About Cell cycle checkpoint control protein RAD9A
Cell cycle checkpoint control protein RAD9A (RAD9A) is a protein
from Homo sapiens identified by UniProt accession
Q99638, 391 residues long.
MolForge cross-references it against 0 known binders and
87 disease associations.
Target properties
| Protein name | Cell cycle checkpoint control protein RAD9A |
| UniProt accession | Q99638 |
| Gene | RAD9A |
| Organism | Homo sapiens |
| Length | 391 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (87)
Diseases linked to this target (Open Targets).
- breast adenocarcinoma · score 0.28
- lung adenocarcinoma · score 0.28
- endometrial cancer · score 0.27
- neurodegenerative disease · score 0.23
- gastric adenocarcinoma · score 0.17
- mean corpuscular hemoglobin · score 0.12
- mean corpuscular volume · score 0.12
- red blood cell density measurement · score 0.08
- body weight · score 0.08
- insulin like growth factor measurement · score 0.08
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q99638-F1 | alphafold | PREDICTED | 75.99 | — |
Amino-acid sequence (391 residues)
MKCLVTGGNV KVLGKAVHSL SRIGDELYLE PLEDGLSLRT VNSSRSAYAC FLFAPLFFQQ YQAATPGQDL LRCKILMKSF LSVFRSLAML EKTVEKCCIS LNGRSSRLVV QLHCKFGVRK THNLSFQDCE SLQAVFDPAS CPHMLRAPAR VLGEAVLPFS PALAEVTLGI GRGRRVILRS YHEEEADSTA KAMVTEMCLG EEDFQQLQAQ EGVAITFCLK EFRGLLSFAE SANLNLSIHF DAPGRPAIFT IKDSLLDGHF VLATLSDTDS HSQDLGSPER HQPVPQLQAH STPHPDDFAN DDIDSYMIAM ETTIGNEGSR VLPSISLSPG PQPPKSPGPH SEEEDEAEPS TVPGTPPPKK FRSLFFGSIL APVRSPQGPS PVLAEDSEGE G
Explore Cell cycle checkpoint control protein RAD9A with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets